Context Therapeutics Outlines Post-ADC T-Cell Engager Strategy, Teases Q2 Claudin 6 Data [Yahoo! Finance]
Context Therapeutics Inc. (CNTX)
Company Research
Source: Yahoo! Finance
solid tumors , advancing three programs—Claudin-6 and mesothelin in clinic and nectin-4 entering the clinic—while expecting Claudin-6 Phase 1a data in Q2 and mesothelin data mid-year, with an initial focus on ADC-exposed, platinum-resistant ovarian cancer. The company emphasizes differentiated safety/efficacy designs to avoid on-target, off-tumor toxicity—using a high-affinity CD3 for Claudin-6, a lower-affinity mesothelin binder targeting the cell-surface fragment, and a pH-dependent dual-masking approach for nectin-4 with a clean tox profile in GLP testing. Context is adapting to emerging industry trends by exploring less-frequent dosing (e.g., every-three-weeks) to limit T-cell exhaustion and plans a Q2 webinar update, while pursuing full regulatory approvals rather than assuming accelerated pathways. Interested in Context Therapeutics Inc.? Here are five stocks we like better. Context Therapeutics (NASDAQ:CNTX) is focused on developing T-cell engager (TCE) therapies for so
Show less
Read more
Impact Snapshot
Event Time:
CNTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CNTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CNTX alerts
High impacting Context Therapeutics Inc. news events
Weekly update
A roundup of the hottest topics
CNTX
News
- Context Therapeutics (CNTX) had its "buy" rating reaffirmed by D. Boral Capital. They now have a $9.00 price target on the stock.MarketBeat
- Context Therapeutics (CNTX) had its "buy" rating reaffirmed by Guggenheim. They now have a $5.00 price target on the stock.MarketBeat
- Context Therapeutics (CNTX) had its price target raised by Piper Sandler from $4.00 to $7.00. They now have an "overweight" rating on the stock.MarketBeat
- Context Therapeutics Reports Full Year 2025 Operating and Financial Results [Yahoo! Finance]Yahoo! Finance
- Context Therapeutics GAAP EPS of -$0.38 [Seeking Alpha]Seeking Alpha
CNTX
Sec Filings
- 3/23/26 - Form S-8
- 3/23/26 - Form 8-K
- 3/23/26 - Form 10-K
- CNTX's page on the SEC website